Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Meningioma × TIC10 compound × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioma 5 Glioblastoma 3 Endometrial Neoplasms 3 Diffuse Intrinsic Pontine Glioma 3 Triple Negative Breast Neoplasms 2 Neoplasm Metastasis 2 Multiple Myeloma 2 Unspecified Adult Solid Tumor 1 Solid Tumors 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Obesity 1 Neuroendocrine Tumors 1 Myelodysplastic Syndromes 1 Meningioma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Leukemia, Myeloid, Acute 1 Gliosarcoma 1 Fallopian Tube Neoplasms 1 Endometrial Cancer Recurrent 1 Disease 1 Carcinosarcoma 1 Breast Neoplasms, Male 1 Advanced Glioblastoma 1

Interventions

Magnetic Resonance Spectroscopy 14 Hydroxyurea 7 Everolimus 7 lutetium Lu 177 dotatate 6 gallium Ga 68 dotatate 6 Radiosurgery 6 Proton Therapy 6 Specimen Handling 5 Bevacizumab 5 pembrolizumab 4 Surveys and Questionnaires 4 Radiotherapy 4 Imatinib Mesylate 4 Cyclophosphamide 4 Tranexamic Acid 3 Temozolomide 3 Surgical Procedures, Operative 3 Sunitinib 3 Radiotherapy, Intensity-Modulated 3 Observation 3 Nivolumab 3 Ga(III)-DOTATOC 3 90Y-octreotide, DOTA-Tyr(3)- 3 trametinib 2 fludarabine 2 arginyllysine 2 aldesleukin 2 Yoga 2 Whole Body Imaging 2 Sodium Chloride 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06012929 2026-01-26

A Study of ONC201 for Refractory Meningioma

University of Nebraska

Phase 2 Withdrawn

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡